Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.

Authors :: Legros L
Guilhot J
Huault S
Mahon FX
Preudhomme C
Guilhot F
Hueber AO
Source :: Leukemia research [Leuk Res] 2014 Jun; Vol. 38 (6), pp. 662-5. Date of Electronic Publication: 2014 Feb 01.
Publication Year :: 2014
Abstract: In chronic myeloid leukemia (CML), evidence is supporting the role of VEGF in growth, and survival of leukemia cells. The evaluation of plasma VEGF levels in 403 CML patients randomized within SPIRIT study to received imatinib-400mg versus imatinib+cytarabine versus imatinib+interferon (IFN) versus imatinib-600mg demonstrated that VEGF is an independent factor of BCR-ABL burden. VEGF low levels at diagnosis were associated with a progression-free survival of 100% at 48 months. Under treatment, significant lowest levels were observed in imatinib+IFN arm. These results support the use of VEGF as a parameter to predict CML evolution and let us to speculate about antiangiogenic properties of IFN.<br /> (Copyright © 2014 Elsevier Ltd. All rights reserved.)

Subjects :: Adult
Aged
Aged, 80 and over
Female
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality
Male
Middle Aged
Vascular Endothelial Growth Factor A blood
Benzamides administration & dosage
Interferons administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Piperazines administration & dosage
Protein Kinase Inhibitors administration & dosage
Pyrimidines administration & dosage

Full Text Access

Tools